---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000078"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:58:25.297570+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038

## Summary
- Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).
- Prior settlements with Sandoz, Teva, and Lupin allow generic entry from March 1, 2038, subject to earlier triggers.
- All ANDA-filing companies now settled, blocking generic competition until at least 2038, a significant IP win.
- Settlements require FTC/DOJ review but are standard in Hatch-Waxman litigation.

## SEC filing metadata
- accession: 0000914475-23-000078
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/0000914475-23-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/nbix-20231110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000078
- JSON: https://secwatch.observer/filing/0000914475-23-000078.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.